Why the study?
Does intranasal enviroxime improve clinical scores in volunteers infected with human rhinovirus type 9?
Population
Volunteers challenged with human rhinovirus type 9
Comparison
Intranasal enviroxime given 6 times a day… vs Placebo
Design
RCT, double-blind
Follow-up
5 days
Authors
Loading...
Intranasal enviroxime lacks clinically meaningful efficacy against rhinovirus; challenges further development as antiviral therapy.
Does intranasal enviroxime improve clinical scores in volunteers infected with human rhinovirus type 9?
Intranasal enviroxime showed limited efficacy against human rhinovirus type 9, with significant reduction in clinical score only on day 5 but no significant reduction in total clinical score or nasal secretions.
Phillpotts et al. (1983) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: